hVIVO is the new name for Retroscreen Virology.
We are experts in a field where people lead the way. The demand for new treatments in the drive towards a healthier world is a pressing one. There is a real need to better understand the true causes of debilitating and life threatening conditions and identify the best way to alleviate or cure them. However, the process of bringing new, affordable treatments to market is complex, costly, high risk and long.

Our approach is radically simple. We develop human models of disease that enable organisations to discover better drugs and diagnostics and accelerate new product validation.

Our belief is that real people hold the key to understanding human biology and this radically simple concept is opening up a brave new world of breakthrough science. hVIVO has established itself as the world leader in human challenge models.

Type
Public
HQ
London, GB
Founded
1998
Employees
397 (est)

hVIVO Locations

London, GB

hVIVO Metrics

hVIVO Summary

Founding Date

1998

Market capitalization

£134 M

Closing share price

£1.72

hVIVO Financials

FY, 2013FY, 2014FY, 2015

Revenue

£27.5 M£18.5 M£7.72 M

Revenue growth, %

-32.8%-58.2%

Cost of sales

£19.2 M£13 M£5.27 M

Gross profit

£8.31 M£5.47 M£2.45 M

Gross profit Margin, %

30.2%29.6%31.8%

Operating expense total

£9.72 M£28.5 M£24.4 M

hVIVO Market Value History

hVIVO Online Presence

hVIVO Company Life

You may also be interested in